As STIM1 glycosylation plays a relevant role in the development of apoptosis upon treatment with the SERCA inhibitor TG in non-tumoral breast cells, the lack of effect of STIM1 glycosylation in SOCE and apoptosis in breast cancer cells might be attributed to a mechanism to evade apoptosis in these cells. This evidence concerns the gene STIM1 and breast carcinoma.